27 completed, 1 terminated, 1 withdrawn. 26 Phase 1, 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 26 | Completed 25, Withdrawn 1 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow Treatment D: new trials by email Literature Review of Treatment D trials Research Report on Treatment D
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn How Different Tablets of the Study Medicine Mevrometostat Are Taken up Into the Blood in Healthy Adults Treatment A, Treatment B, Treatment C - Healthy | Phase 1 | Withdrawn | Pfizer | 2025-04-28 | 2025-04-24 | |
| Electrophysiological Effects of Potential QT Prolonging Drugs Clarithromycin, Pimozide, Placebo (Part 1) - Drug-induced QT Prolongation, Pharmacokinetics | Phase 1 | Completed | Food and Drug Administration (FDA) | 44 | 2023-03-21 | 2023-06-22 |
| Relative Bioavailability of Evobrutinib Tablet Batches Treatment A, Treatment B, Treatment C - Healthy | Phase 1 | Completed | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 28 | 2023-01-18 | 2025-12-23 |
| A Study to Learn About the Study Medication, Zavegepant, in Healthy Volunteers Zavegepant 100mg non-enteric coated soft gel capsule, Zavegepant 100mg immediate release tablet, Zavegepant 2 x 100mg immediate release tablets - Biological Availability | Phase 1 | Completed | Pfizer | 52 | 2022-08-24 | 2024-10-01 |
| P-glypoprotein Inhibition Effect on the Pharmacokinetics of Two Tacrolimus Formulations: Prolonged and Extended-release Treatment A, Treatment B, Treament C - Pharmacokinetics | Phase 2 | Completed | Rennes University Hospital | 27 | 2022-02-15 | 2024-12-11 |
| To Evaluate the Pharmacokinetic Drug Interactions, Safety and Drug Tolerance in Healthy Volunteers Treatment A, Treatment B, Treatment C - Healthy | Phase 1 | Completed | JW Pharmaceutical | 40 | 2022-01-17 | 2022-07-19 |
| Study to Assess the Bioavailability of Different Formulations of AZD9977 and Dapagliflozin and Influence of Food in Selected Formulations in Healthy Volunteers Treatment A, Treatment B, Treatment C - Heart Failure | Phase 1 | Completed | AstraZeneca | 20 | 2021-06-29 | 2021-09-09 |
| Efficacy and Safety of CHF 6532 in Patients With Uncontrolled Severe Eosinophilic Asthma Treatment A, Treatment B, Treatment C - Asthma; Eosinophilic | Phase 3 | Terminated | Chiesi Farmaceutici S.p.A. | 810 | 2019-08-28 | 2022-04-08 |
| Evaluate Taste and Relative Bioavailability of Two Microsphere Formulations of Crizotinib in Healthy Participants Treatment A, Treatment B, Treatment C - Healthy Volunteers | Phase 1 | Completed | Pfizer | 25 | 2019-06-12 | 2019-11-15 |
| A Four-way Crossover Study of 3 Formulations of M207 With Intranasal Zolmitriptan in Healthy Volunteers M207 3.8 mg "Sled" (two 1.9 mg patches made on a "Sled" coater, foil pouches), M207 3.8 mg "MACAP" (two 1.9 mg patches made on a "MACAP" coater, foil cups), M207 3.8 mg "MiniMac" (two 1.9 mg patches made on a "MiniMac" coater, foil cups - Migraine | Phase 1 | Completed | Zosano Pharma Corporation | 24 | 2019-05-29 | 2021-11-18 |
| PK Linearity and Steady State PK of CHF 6532 in Healthy Subjects Treatment A, Treatment B, Treatment C - Asthma | Phase 1 | Completed | Chiesi Farmaceutici S.p.A. | 30 | 2019-05-10 | 2020-07-22 |
| A Study to Assess the Reaction of Body for Four Different Formulations of AZD9977 (Part A) and Influence of Food and Lower Dose of a Selected Formulation (Part B) in Healthy Male Subjects Treatment A, Treatment B, Treatment C - Heart Failure | Phase 1 | Completed | AstraZeneca | 12 | 2019-02-05 | 2021-04-19 |
| A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants Treatment A, Treatment B, Treatment C - Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs), Healthy Participants | Phase 1 | Completed | AstraZeneca | 24 | 2018-09-05 | 2018-11-08 |
| To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers Treatment A, Treatment B, Treatment C - HIV Infections | Phase 1 | Completed | ViiV Healthcare | 36 | 2018-02-26 | 2019-12-09 |
| A Study to Evaluate the Disposition of Drug in Body and Safety After Administration of Single Inhaled Doses of Drugs Abediterol and AZD7594 Administered Alone, in Fixed Dose Combination and in Free Combination Using the Dry Powder Inhaler in Healthy Male Participants Abediterol, AZD7594, AZD7594/abediterol - Chronic Obstructive Pulmonary Disease (COPD), Asthma | Phase 1 | Completed | AstraZeneca | 14 | 2016-11-24 | 2018-02-13 |
| Comparative Pharmacokinetics and Food-Effect Bioavailability of Lubiprostone Sprinkle in Healthy Volunteers Cohort 1: Lubiprostone Capsule, Fasted, Cohort 1: Lubiprostone Sprinkle Formulation, Fasted, Cohort 2: Lubiprostone Sprinkle Formulation, Fed - Healthy Volunteers | Phase 3 | Completed | Sucampo Pharma Americas, LLC | 49 | 2016-11-16 | 2020-03-09 |
| Study to Assess the Bioavailability of Ticagrelor OD Tablet vs. IR Tablet Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water, Ticagrelor OD tablet (90 mg single dose) administered without water, Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube - Bioavailability, Healthy Subjects | Phase 1 | Completed | AstraZeneca | 100 | 2015-06-01 | 2016-09-29 |
| A Bioavailability Study With Alternate Methods of Administration of Naloxegol Tablets, and Solution Naloxegol 25 mg tablet, crushed, suspended in water, given orally, Naloxegol 25mg tablet crushed, suspended in water, given via nasogastric tube, Naloxegol 25 mg (10 mL oral solution) - Bioavailability, Healthy Subjects | Phase 1 | Completed | AstraZeneca | 44 | 2015-05-01 | 2017-03-10 |
| A Crossover Study to Evaluate Relative Bioavailability of Simeprevir Age-appropriate Oral Formulation Candidates Compared With 150-milligram (mg) Oral Capsule in Healthy Adult Participants Treatment A, Treatment B, Treatment C - Healthy | Phase 1 | Completed | Janssen Sciences Ireland UC | 48 | 2015-04-28 | 2017-09-07 |
| A Trial In Healthy HIV-Negative Women To Assess The Effect Of Menses And Tampon Use On The Pharmacokinetics Of Dapivirine, Delivered By Dapivirine Vaginal Ring-004, Containing 25 Mg Of Dapivirine Dapivirine Vaginal Ring-004 and no tampons, Dapivirine Vaginal Ring-004 with tampons, Dapivirine Vaginal Ring-004 with no menses - HIV | Phase 1 | Completed | International Partnership for Microbicides, Inc. | 16 | 2015-01-12 | 2017-09-06 |
Showing 20 of 29. Sign in to see all of them.
Asthma (3) · Heart Failure (2) · HIV Infections (1) · Hypertension (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Migraine Disorders (1) · Neurofibromatosis 1 (1) · Pulmonary Disease, Chronic Obstructive (1) · Pulmonary Eosinophilia (1)
Pfizer (7) · AstraZeneca (6) · Chiesi Farmaceutici S.p.A. (2) · Boehringer Ingelheim (1) · Food and Drug Administration (FDA) (1) · Gilead Sciences (1) · International Partnership for Microbicides, Inc. (1) · JW Pharmaceutical (1) · Janssen Research & Development, LLC (1) · Janssen Sciences Ireland UC (1) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (1) · Merck Sharp & Dohme LLC (1) · Rennes University Hospital (1) · Sucampo Pharma Americas, LLC (1) · Tibotec BVBA (1)
United States (9) · Germany (5) · Singapore (4) · Belgium (2) · United Kingdom (2) · Bulgaria (1) · France (1) · South Korea (1)
Rainard Fuhr, Dr. med. (2) · Alen Jambrecina (1) · Don Kellerman, PharmD (1) · Jennifer Boston, MSN, APNP (1) · Michael Hawkins, MD (1) · Min-Gul Kim, PI (1) · Ozan Dursun (1) · Pablo Forte Soto, MD, MSc, PhD (1)
PMID 33834354, PMID 34817414, PMID 35170228, PMID 35410754, PMID 41920422
2014 (1), 2018 (1), 2019 (1)